The Difference in Informed Prostate Cancer Risk Screening

Offering physicians and patients a comprehensive, highly accurate risk assessment data set for prostate cancer care decisions.


MyProstateScore 2.0

Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.

Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.

MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for providers and both biopsy naïve and prior negative patients.

You deserve the next generation in prostate cancer risk prediction for men’s health.

How It Works

Our Science. Clear Results. Your Decision.

A simple urine test that shines a highly sensitive light on a patient’s actual risk of prostate cancer when PSA is elevated. Our data models have combined those clinical factors most relevant for both biopsy naïve and prior negative patient populations. Our goal is to provide a solution with zero surprises for all involved.

Urine Sample icon

Simple Urine

It takes just 30 seconds, is non-invasive, and opens the door to peace of mind, with a 95%–-99% accurate prediction of risk for cancer.

Magnifying Glass icon

18 Biomarker
Array Analysis

MPS2 analyzes urine in an array of 18 genetic biomarkers including T2:ERG — the most specific prostate cancer biomarker available for identifying prostate cancer risk.

Report icon

Clear Patient
Risk Report

Determine your recommended best course of action based on an easy-to-read visual and technical illustration of patient risk factors.

Why Lynx Dx?

Lynx Dx provides best-in-class diagnostic testing services to help people live healthy and productive lives. We exist to support positive public health.

MPS2 is a comprehensive, personalized biomarker available for patients who have had prior negative biopsies. They often tend to avoid repeat sampling, if indicated. A low risk result provides confidence for observation that both my patient and I can rely on."

— Adam Ball, MD

PSA screening is one of the most controversial issues in medicine, not only for urologists and clinicians but also and most importantly for our patients. MyProstateScore 2.0 is a wonderful addition to the armamentarium we have available to help us assist our patients when they face an elevated PSA and have a fear of what to do next."

— Ali Kasraeian, MD, MHA, FACS

The MPS2 report with the speedometer graphic enables me to easily decipher the report and to better explain the results and my recommendations to patients."

— Ella Anastasiades, PA-C

The decision to proceed with a repeat biopsy in the setting of a prior negative sampling can be challenging. Being able to easily show my patient his specific risk of having clinically significant prostate cancer has made these conversations much easier and understandable for my patients.”

— Michael Cookson, MD

Having as much information as possible is important. MPS2 provides an extra unbiased layer to guide us along with the DRE, PSA level, MRI and clinical factors such as age, race and family history. Knowing your patient and his desires with these tools will help with decision making."

— Sabry Mansour, MD

Elevated tumor markers are central in my decision making about ordering a biopsy. I use an MRI after deciding to do a biopsy, to determine if the patient will have a standard biopsy or a fusion biopsy."

— Tony Altamirando, PA-C


Early Prostate Cancer Risk Assessment

One in eight men will receive a prostate cancer diagnosis during their lifetime. The good news? Survival is nearly 100% when diagnosed early and contained within the prostate. When it spreads, however, the five-year survival is just 31%.

Early detection is critical for you and your family.

You can avoid subjective, invasive tests and receive a highly accurate prostate cancer screening to assess your current risk.

MyProstateScore 2.0 can give you and your urologist accurate data to make a personalized healthcare decision for you.

Stay Up-To-Date


Industry news, men’s health information, and expert prostate cancer and risk assessment research.